# PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA

> **NCT04015622** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **British Columbia Cancer Agency** · enrollment: 100 (estimated)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04015622
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-07
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04015622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04015622, "PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04015622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*